4//SEC Filing
Nabriva Therapeutics Plc 4
Accession 0001104659-17-041907
CIK 0001703287other
Filed
Jun 26, 8:00 PM ET
Accepted
Jun 27, 9:56 PM ET
Size
8.4 KB
Accession
0001104659-17-041907
Insider Transaction Report
Form 4
Webster Stephen W
Director
Transactions
- Other
Stock Option
2017-06-23+20,200→ 20,200 totalExp: 2026-08-25→ Ordinary Shares (20,200 underlying) - Other
Stock Option
2017-06-23+10,100→ 10,100 totalExp: 2026-08-25→ Ordinary Shares (10,100 underlying)
Footnotes (5)
- [F1]The exercise price is 6.634 Euro.
- [F2]Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc.
- [F3]This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2019. This option vests on a monthly pro-rata basis at the end of each successive month following August 31, 2016.
- [F4]The exercise price is 6.634 Euro.
- [F5]This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017.
Documents
Issuer
Nabriva Therapeutics Plc
CIK 0001703287
Entity typeother
IncorporatedIreland
Related Parties
1- filerCIK 0001703287
Filing Metadata
- Form type
- 4
- Filed
- Jun 26, 8:00 PM ET
- Accepted
- Jun 27, 9:56 PM ET
- Size
- 8.4 KB